Independent evaluation criteria
For people considering ibogaine, families, and advocates, this page sets out practical evidence to request before engaging with any program. It is a framework for asking clear questions about safeguards in a high-risk intervention—not medical or legal advice.
Before engagement
A credible intake process should gather a full medical history, current and recent medication use, substance use, allergies, prior reactions, and relevant family history. It should explicitly address pregnancy and psychiatric history, including current symptoms and previous episodes that may affect risk assessment. The FDA’s drug-safety communication process illustrates why medication risk information should be handled as a specific clinical question, not a generic intake box.
Ask what information is reviewed before a person is accepted, who reviews it, how unanswered questions are resolved, and what circumstances lead to postponement or refusal. Program descriptions found through ibogaine treatment location directories can help identify options, but the same screening evidence should be requested from each program directly.
Mandatory cardiac workup
Ibogaine has been associated with QT interval prolongation and serious cardiac risk. The medical literature includes documented adverse outcomes, and the overview of ibogaine’s reported pharmacology and safety concerns is a useful starting point for understanding why broad claims of safety are not enough.
A program should be able to specify whether it obtains an ECG, checks electrolytes, calculates or reviews QTc, considers relevant cardiac history, and uses defined thresholds for exclusion or further evaluation. Where a program refers to specialist clearance, ask what a cardiologist is asked to review and how that decision is documented. A Florida ibogaine treatment option should be assessed against the same standards as any program elsewhere.
Verify independently: ask for the timing of ECG and laboratory work, how abnormal findings are handled, whether repeat testing occurs when clinically indicated, and what monitoring is available during the period of greatest concern.
A three-part review
Request a clear explanation of resuscitation equipment, monitoring, trained personnel, emergency medication access, and transfer plans. The American Heart Association’s CPR resources underscore the importance of timely preparedness when cardiac emergencies occur.
Programs should be able to describe the stated source, identity, purity testing, dose range, route, observation period, and any repeat-dosing policy. When examining Texas ibogaine policy discussions, separate policy interest from evidence that a particular program discloses its own procedures.
If a program performs any invasive procedure, request its infection-control and sterile-procedure standards, supplies, staff training, and process for responding to a suspected infection. Facilities listed as ibogaine detox centers should still provide answers that are specific to the care they offer.
Compare like with like
Different legal settings, travel arrangements, and marketing language do not remove the need for a consistent safety review. Whether a person is considering ibogaine treatment in Utah, looking at European ibogaine programs, or weighing an ibogaine retreat in Mexico, compare the actual evidence supplied for screening, monitoring, emergency response, and follow-through.
Use the program’s written information alongside the questions in the site’s program comparison matrix. If a program cannot or will not explain a key safeguard in enough detail to verify it, record that as an unresolved issue rather than filling in the gap with assumptions.
After the acute period
A complete review includes what happens after the immediate intervention: how a program plans discharge, recognizes deterioration, supports continuity, and communicates limits on what it can provide. A provider should not substitute aspirational promises for a concrete, individualized plan. The SAMHSA National Helpline information is one example of an established pathway for finding treatment referral support in the United States.
Ask how the program addresses transition, family involvement where appropriate, ongoing mental health or substance-use care, and urgent concerns after departure. For a structured way to consider that period, review the site’s aftercare and integration considerations; they can help separate a stated intention from a workable continuity plan.
For local comparison, a Tijuana ibogaine clinic listing should be assessed with the same questions about documented safeguards, emergency access, and post-program planning as any other setting.
“A program is easier to evaluate when it can state what it screens for, what it measures, what it will not do, and what it does if conditions change.”
Questions to keep asking
A program should be able to describe its intake process, medication review, medical and psychiatric screening, cardiac workup, emergency readiness, dosing policy, and follow-through plan in plain language. The broader evaluation approach described on the Vigilance Oak main resource can help keep those questions organized.
Medication and substance-use history can affect cardiac risk, interactions, withdrawal management, and the appropriateness of participation. A review should not be treated as a formality; it should result in clear questions, documented decisions, and appropriate referral when the program cannot safely resolve an issue.
It includes clear information about monitoring, emergency equipment, trained personnel, escalation procedures, and transfer arrangements appropriate to the setting. The standards behind this independent approach are described in Vigilance Oak’s stated purpose and principles.
Use the checklist deliberately
Written protocols, clear thresholds, accountable emergency plans, and realistic follow-through are more useful than broad assurances. This page is an independent resource for organizing questions before a high-risk decision.